The Trump administration has just announced the formation of a working group at the Food and Drug Administration to study legalizing the importation of foreign-made drugs. Although the study is limited to a narrow set of circumstances in which imports might be allowed, it sets us on a path we shouldn't step on.
The goal is to lower costs and prevent price-gouging by drug makers who find themselves with monopoly power over a particular treatment, say, an out-of-patent medication for a rare disease with only a single generic manufacturer in the market. But proponents of imports are only starting with the narrow case. Their real goal is to allow foreign imports on a massive scale.
Unfortunately, their efforts are based on a mistaken premise. Legalizing drug importation would not generate substantial savings. Worse, it could expose millions of Americans to dangerous counterfeit drugs.
Several states have tried importation schemes in the past, and they've all failed.
Illinois, for instance, spent $1 million in taxpayer dollars launching its "I-Save-Rx" program. After much fanfare, only 0.02 percent of the population took advantage of the program during its first year and a half. The state ended the program shortly thereafter.
A similar program in Minnesota filled less than 140 prescriptions per month, while one in Boston had just a couple dozen takers. Vermont's attempt never even got off the ground.
If Canadian drugs were really as cheap as importation advocates claim, why have all these small-scale importation experiments failed? Why haven't patients flocked to them?
Because the price disparity isn't nearly as great as importation advocates claim. In fact, about 85 percent of all medicines consumed in the United States are actually less expensive than those in Canada or Europe.
Consider Lipitor: a 30-day supply of the popular cholesterol medication can cost more than $200. But the same supply of the generic version can cost as little as $4. Buy the same generic supply from CanadaPharmacyOnline.com, and it'll cost more than $14. That's a cost 250 percent higher.
The savings from bringing Canadian drugs stateside are small to nonexistent. In fact, the Department of Health and Human Services estimates that legalizing importation for the entire nation would drop total American drug spending by less than one percent.
Patients also may be leery of foreign drugs for safety reasons — and rightly so. The production standards and quality controls are much weaker in foreign nations.
Most drugs coming in from Canada aren't actually Canadian in origin. According to the FDA, 85 percent actually come from other, less developed, countries. And Canadian authorities offer no guarantees of authenticity and safety.
The world is awash in counterfeit drugs. In just one week last summer, international agents seized 25 million illicit and counterfeit drugs worldwide.
From the standpoint of reducing costs, foreign drug importation is a bad idea; from a safety standpoint, it's even worse.
The FDA working group has been asked how the import process can be made safe. Even under the narrow circumstances the FDA is considering, the honest answer is that it can't be.
Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest.